Coronavirus Stock Market Opportunities Based on Algorithmic Trading: Returns up to 28.04% in 1 Month

Coronavirus Stock Market Opportunities

This Coronavirus Stock Market Forecast identifies the most affected stocks in negative way while also highlighting the opportunities arising in the stock market during these extraordinary market situation. The package covers the assets that may be affected by the coronavirus with the biggest financial exposures and it includes assets such as gold and relevant commodities, biotech companies’ stocks, pharmaceutical companies’ stocks, semiconductors and technological sectors stocks and more.

  • Top 10 stocks for the long position
  • Top 10 stocks for the short position

Package Name: Coronavirus Stock Market Forecast
Recommended Positions: Long
Forecast Length: 1 Month (3/16/22 – 4/16/22)
I Know First Average: 4.57%
Coronavirus Stock Market Opportunities
Coronavirus Stock Market Opportunities chart

I Know First’s State of the Art Algorithm accurately forecasted 7 out of 10 trades in this Coronavirus Stock Market Forecast Package for the 1 Month time period. ESPR was our the best stock pick with a return of 28.04%. Additional high returns came from FCX and BURL, at 11.09% and 8.92% respectively. The Coronavirus Stock Market Forecast package had an overall average return of 4.57%, providing investors with a premium of 1.52% over the S&P 500’s return of 3.05%.

Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

As of December 31, 2016, the Company had completed Phase II clinical studies of bempedoic acid. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.